Niagen Bioscience Inc (NASDAQ:NAGE) reported its fourth quarter and full-year 2025 financial results, delivering a top-line performance that exceeded analyst expectations. The company, focused on healthy aging through its proprietary NAD+ precursor ingredient Niagen®, posted strong sales growth for the year, though its bottom-line results presented a more complex picture when compared to the prior year period.
Earnings and Revenue Versus Estimates
For the fourth quarter, Niagen Bioscience reported net sales of $33.8 million, a 16% increase year-over-year. This figure came in above the analyst consensus estimate of $32.3 million. The company's flagship consumer brand, Tru Niagen®, was the primary growth driver, with sales rising 21% to $27.5 million.
On the earnings front, the company reported net income of $4.1 million, or $0.05 per basic and diluted share. This represents a decline from the $7.2 million, or $0.09 per share, reported in Q4 2024. The company's non-GAAP adjusted earnings per share for the quarter was $0.03. This result narrowly surpassed the analyst estimate for non-GAAP EPS of $0.0224.
The year-over-year decline in quarterly net income is largely attributable to elevated operating expenses and the absence of certain one-time benefits recorded in the prior-year period. Specifically, Q4 2024 benefited from a $3.5 million reversal of previously accrued royalties and a $1.3 million recovery related to a legal settlement. The current quarter did include a $2.0 million gain from the settlement of royalty obligations, but this was not enough to offset the higher baseline expenses.
Full-Year Highlights and Forward Outlook
The full-year 2025 results painted a picture of robust operational growth:
- Net sales increased 30% to $129.4 million.
- Net income more than doubled to $17.4 million, up from $8.6 million in 2024.
- Gross margin expanded by 250 basis points to 64.3%.
- The company ended the year with a strong cash position of $64.8 million and no debt.
Management provided an outlook for 2026, projecting net sales growth of 10-15% year-over-year, excluding revenue from a recently divested segment. This guidance implies a revenue range of approximately $142 million to $148 million. This outlook sits below the current analyst consensus estimate for 2026 sales of $156.3 million, which may factor into investor sentiment.
Market Reaction and Price Action
Following the earnings release, the stock has experienced downward pressure in after-hours and recent trading sessions. This reaction suggests the market is weighing several factors:
- Positive: The clear top-line beat on both quarterly and annual sales, demonstrating strong consumer demand.
- Mixed: The bottom-line decline in the quarter despite the EPS beat, highlighting increased investment and the impact of non-recurring items.
- Cautious: The company's 2026 sales growth guidance, which, while healthy, appears more conservative than existing Wall Street forecasts.
The market's response indicates a focus on future growth trajectory and profitability amidst rising investments in sales, marketing, and pharmaceutical development, as outlined in the company's 2026 expense outlook.
Key Operational Developments
Beyond the financials, the press release highlighted several strategic moves:
- Portfolio Expansion: The November 2025 launch of Tru Niagen® Beauty, entering the nutricosmetics category.
- IP Consolidation: The December 2025 acquisition of the core nicotinamide riboside patent portfolio from Queen’s University Belfast, securing foundational intellectual property.
- Sales Channel Development: A January 2026 partnership enabling U.S. customers to use HSA/FSA funds to purchase Tru Niagen®.
- Portfolio Pruning: The February 2026 sale of the non-core Analytical Reference Standards and Services segment for approximately $6 million in cash.
For a detailed breakdown of historical earnings, future estimates, and additional financial metrics, investors can review the data available on the Niagen Bioscience earnings page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, investment recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
